Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNX-2440 in recurrent glioblastoma
NCT03714334Phase 1Terminated
- Sponsor
- Universidad de Navarra
- Start
- Oct 2018
- Primary completion
- Apr 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tezemlimogene daxadenorepvec in glioblastoma (GBM), sponsored by Universidad de Navarra. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 8 weeks. Started Oct 2018; status: terminated.
02
Drugs
tezemlimogene daxadenorepvec
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03714334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714334.